Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2016 Earnings Presentation
17 slides from Dr. Lal Pathlabs's earnings presentation, May 27, 2016
Slide 1: Dr. Lal PathLabs Limited (LPL) Q4 & FY16 Results Presentation
Dr. Lal PathLabs Limited (LPL) Q4 & FY16 Results Presentation May 27, 2016
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q4 & FY2016 Financial Performance 4 Financial Trends 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Co
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 172 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,559 Patient Service diagnostic services Centers (PSCs) and 4,967 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Focused on long-term growth and value creation Scale up in network progressing as per strategy, driving overall growth; Continued addition of centres During FY16 LPL reported: Revenue growth of 20% to Rs. 7,913 mn from Rs. 6,596 mn EBITDA (without ESOP Reversal) increase of
Slide 5: Notes to Accounts
Notes to Accounts ESOP charges amounting to Rs. 35 mn have been reversed during Q4 FY16. EBITDA and PBT discussion in this note focusses on EBITDA and PBT performance without the prior period ESOP expenses reversal to provide a fair picture of the Company’s normal business results during the qua
Slide 6: Q4 & FY Financial Performance
Q4 & FY Financial Performance Particulars (Rs. mn) Q4 FY16 Q4 FY15 Growth % FY16 FY15 Growth % Revenues 1,977 1,718 15.1% 7,913 6,596 20.0% Total Expenditure 1,436 1,286 11.7% 5,816 5,036 15.5% EBITDA 554 444 24.8% 2,148 1,589 35.1% EBITDA (without ESOP reversal) 520 449 15.8% 2,113 1,831 15.4% Marg
Slide 7: Financial Trends: Revenues
Financial Trends All figures in Rs mn Revenues Revenues 1,977 7,913 1,718 6,596 Q4FY15 Q4FY16 FY15 FY16 Q4 FY16 revenues enhanced by 15% YoY driven by growth witnessed in volumes in combination with stable realizations Excluding the favourable impact on account of increased testing for Swine Flu
Slide 8: Financial Trends: EBITDA
Financial Trends All figures in Rs mn EBITDA (Without ESOP Reversal) 520 2,113 1,831 449 Q4FY15 Q4FY16 FY15 FY16 EBITDA (Without ESOP Reversal) delivered 15% improvement during FY16, gains in Q4 FY16 stand at 16% EBITDA Margins (Without ESOP Reversal) stood at 26.7% for FY16 and at 26.3% for Q4
Slide 9: Financial Trends: PBT
Financial Trends All figures in Rs mn PBT (Without ESOP Reversal) 493 1,973 1,639 395 Q4FY15 Q4FY16 FY15 FY16 PBT (Without ESOP Reversal) growth during Q4 FY16 and FY16 stood at 25% and 20% respectively Margins were at 25% during both FY16 and in Q4 FY16 PAT growth in Q4 FY16 and FY16 was at 2
Slide 10: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,559 172 5,668 164 1,340 4,967 4,225 1,064 146 824 2,879 131 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 No. of patients (mn) No. of samples (mn) 26.3 12.0 21.7 19.0 9.9 16.0 9.0 7.7 FY13 FY14 FY15 FY16 FY13 F
Slide 11: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “The momentum of growth for LPL has continued throughout FY 2016 and we await several milestones to mark our growth going ahead too. Our performance during this quarter shows the progr
Slide 12: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services . Initiatives to improve brand c
Slide 13: Corporate Overview
Corporate Overview • LPL Strategy for future growth • Experienced Management team 13
Slide 14: LPL Strategy for future growth
LPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 14
Slide 15: LPL Strategy for future growth
LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Life
Slide 16: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Manoj Garg Shankha Banerjee Chief Financial Officer Chief Human Resources Officer COO – Strategic
Slide 17: Contact us
Contact us About Dr Lal PathLabs Limited (LPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and